FDA Set To Strengthen Inspections Of Chinese Drugmakers In Aftermath Of Heparin Deaths – CDER Official
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's Buhay notes "there will be many multiples" of the current number of inspections following the opening of three new offices in China.
You may also be interested in...
Rx Manufacturing Safety Bill Resurfaces Without Inspection Fees
FDA's foreign and domestic oversight powers would increase under the legislation, which has been stripped down in an apparent effort to speed passage.
Rx Manufacturing Safety Bill Resurfaces Without Inspection Fees
FDA's foreign and domestic oversight powers would increase under the legislation, which has been stripped down in an apparent effort to speed passage.
Innohep Alert Sounded, But This Time Heparin Not Sourced From China
Preliminary data do not suggest a manufacturing problem, but FDA’s ongoing safety review notes the heparin used is still under investigation.